Bronchopulmonary PK of AT-527 (R07496998)

Phase 1CompletedNCT04877769

Atea Pharmaceuticals, Inc.24 enrolled

Overview

This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of AT-527 (R07496998)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Volunteer Study

Interventions

AT-527DRUG

administered twice daily (BID) for 2.5 days (5 doses in total)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must agree to use birth control, as required by the protocol. * Females must have a negative pregnancy test at Screening and prior to dosing * Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2 * Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: * Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2 * Abuse of alcohol or drugs * Use of other investigational drugs within 28 days of dosing * Concomitant use of prescription medications, or systemic over-the-counter medications * Other clinically significant medical conditions or laboratory abnormalities

Locations (1)

Atea Study Site

London, United Kingdom

Outcomes

Primary Outcomes

Concentrations of AT-527 in epithelial lining fluid

Time frame: 4-5 hours after last dose and 11-12 hours after last dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.